Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Publication year range
1.
Gan To Kagaku Ryoho ; 43(9): 1101-3, 2016 Sep.
Article in Japanese | MEDLINE | ID: mdl-27628552

ABSTRACT

A 52-year-old woman presented with redness and swelling with a peau d'orange appearance in the whole right breast. Ultrasound revealed elevated subcutaneus fat density and a diffuse hypoechoic area. She was diagnosed with inflammatory breast cancer(T4dN2M0, Stage III B of the HER2 subtype). After 4 courses of EC treatment as primary systemic therapy, the hypoechoic area was still present. Subsequent chemotherapy with pertuzumab, trastuzumab, and docetaxel was effective, as hypoechoic area was not observed on ultrasound. She underwent mastectomy and axillary dissection, and pathological examination revealed pCR. At present, 2 years after surgery, the patient is alive with no reccurence.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Inflammatory Breast Neoplasms/drug therapy , Neoadjuvant Therapy , Biopsy , Female , Humans , Inflammatory Breast Neoplasms/chemistry , Inflammatory Breast Neoplasms/pathology , Inflammatory Breast Neoplasms/surgery , Mastectomy , Middle Aged , Neoplasm Staging , Receptor, ErbB-2/analysis , Receptor, ErbB-2/metabolism , Treatment Outcome
2.
Am J Hematol ; 69(4): 247-54, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11921018

ABSTRACT

We examined the expression of tissue factor (TF) and vascular endothelial growth factor (VEGF) and the microvessel density (MVD) in 100 patients with colorectal cancer, and we investigated the relationship of the expression of TF or VEGF with angiogenesis. TF antigen was positive in 57.0% of all specimens. Incidence of TF expression was 41.2%, 45.5%, 52.6%, 84.6%, and 81.3% in tumors from patients in clinical stages I, II, IIIA, IIIB, and IV, respectively. TF expression was correlated with the Dukes' classification (P = 0.01) and the clinical stage of colorectal cancer (P = 0.02). VEGF antigen was positive in 64.0% of all specimens. Incidence of VEGF expression was 41.2%, 57.6%, 73.7%, 84.6%, and 75.0% in tumors from patients in clinical stages I, II, IIIA, IIIB, and IV, respectively. VEGF expression was correlated with the Dukes' classification (P = 0.01) but showed a weak association with the clinical stage (P = 0.08). MVD was significantly associated with the depth of invasion (P = 0.01), lymph node metastasis (P = 0.001), and liver metastasis (P = 0.02). The mean values of MVD were 7.5 +/- 2.8, 10.1 +/- 5.7, 14.6 +/- 5.8, 13.5 +/- 3.9, and 15.9 +/- 4.2 in tumors from patients in clinical stages I, II, IIIA, IIIB, and IV, respectively. A close relationship between VEGF and MVD (P < 0.001) and a significant correlation between TF expression and MVD were observed (P = 0.02). TF-positive carcinomas presented high MVD and VEGF expression (P < 0.001) more frequently than did TF-negative tumors. These results suggest that involvement of TF in the process of metastasis and progression of colorectal cancer may depend on increased angiogenesis.


Subject(s)
Colorectal Neoplasms/blood supply , Colorectal Neoplasms/chemistry , Endothelial Growth Factors/analysis , Lymphokines/analysis , Neovascularization, Pathologic/metabolism , Thromboplastin/analysis , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Female , Humans , Immunohistochemistry , Liver Neoplasms/secondary , Lymphatic Metastasis , Male , Microcirculation/pathology , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...